CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today, Portal Biotechnologies, Inc. (“Portal”), a cell engineering platform company, announced a $5M pre-seed round led by Pear VC, with participation from Conscience VC and 10x Capital.

今天，细胞工程平台公司Portal Biotechnologies，Inc.（“Portal”）宣布了一轮500万美元的种子前投资，由Pear VC牵头，良知VC和10x Capital参与。

Portal is implementing a simplified approach to intracellular delivery, focused on accelerating advances in RNA, gene editing, and AI-driven discovery technologies. Portal is committed to ensuring broad accessibility of its platform to enable a variety of research and therapeutic applications. The company was founded by Armon Sharei, Ph.D., founder and former CEO of SQZ Biotechnologies..

门户网站正在实施一种简化的细胞内递送方法，重点是加速RNA，基因编辑和AI驱动的发现技术的进步。门户致力于确保其平台的广泛可访问性，以实现各种研究和治疗应用。该公司由SQZ Biotechnologies的创始人兼前首席执行官Armon Sharei博士创立。

Portal’s initial product suite is based on next generation mechanical delivery technology capable of delivering many different types of cargo into a broad range of cell types. The process relies on transient perturbation of a cell’s membrane as it transits through microscopic holes in a thin, specially designed, silicon surface.

门户网站的初始产品套件基于下一代机械交付技术，能够将许多不同类型的货物交付到各种细胞类型中。该过程依赖于细胞膜通过特殊设计的薄硅表面上的微孔时的瞬时扰动。

This simple approach has been shown to enable delivery of a variety of molecules into cells, including siRNA, mRNA, polypeptides, antibodies and CRISPR RNP complexes, both individually and simultaneously, for multiplexed cell function modification..

这种简单的方法已被证明能够将多种分子单独和同时递送到细胞中，包括siRNA，mRNA，多肽，抗体和CRISPR-RNP复合物，用于多重细胞功能修饰。

“Access to the intracellular space is a critical limitation across biological research, drug development, and cell therapy manufacturing. Thanks to the support of our early investors and partners, Portal is in a strong position to deploy its technology across applications. Our hope is that by providing robust modularized solutions across scales, we will enable novel biological insights, accelerate development of new generation small or large molecules, and streamline cell therapy design and manufacturing,” said Armon Sharei, Ph.D., Founder and CEO of Portal..

“进入细胞内空间是生物学研究、药物开发和细胞治疗制造的关键限制。由于我们早期投资者和合作伙伴的支持，门户网站在跨应用程序部署其技术方面处于有利地位。我们希望通过跨规模提供强大的模块化解决方案，我们将实现新的生物学见解，加速新一代小分子或大分子的开发，并简化细胞疗法的设计和制造，”门户网站创始人兼首席执行官Armon Sharei博士说。

Portal is continuing to expand its ongoing partnerships with several large pharmaceutical and biotechnology companies as well as prominent academic institutions as part of its beta program for early adopters. The focus of these partnerships ranges from generation of multifunctional cell therapies at point-of-care, to high throughput assessment of intracellular target engagement by small molecule and peptide drug candidates.

门户网站正在继续扩大与几家大型制药和生物技术公司以及知名学术机构的持续合作伙伴关系，作为其早期采用者测试计划的一部分。这些伙伴关系的重点从护理点的多功能细胞疗法的产生，到小分子和肽候选药物对细胞内靶标参与的高通量评估。

Under the ‘Powered by Portal’ model, the company is integrating its single-use cartridges with existing high throughput robots and clinical manufacturing equipment..

在“门户驱动”模式下，该公司正在将其一次性墨盒与现有的高通量机器人和临床制造设备进行集成。

“We are very excited to join the Portal team and support their mission to solve one of the field's major long-standing challenges,” said Eddie Eltoukhy, Partner and lead investor from Pear VC. “Through their platform focused business model, we hope to see broad impact across applications that could ultimately benefit many patients.”.

Pear VC合伙人兼首席投资者Eddie Eltoukhy表示：“我们很高兴加入门户团队，支持他们解决该领域长期存在的主要挑战之一的使命。通过他们以平台为中心的商业模式，我们希望看到应用程序产生广泛影响，最终使许多患者受益。”

Beyond Portal’s initial focus on supplying enabling technology for wide ranging research and clinical applications, in the future the company aims to develop a suite of cell modification modules. These modules will contain various cell modifying cargoes that can impart specific functionality in a cell without altering the genome..

除了门户最初专注于为广泛的研究和临床应用提供支持技术之外，该公司未来还将开发一套细胞修饰模块。这些模块将包含各种细胞修饰货物，这些货物可以在不改变基因组的情况下赋予细胞特定功能。

Portal is a member of the Bayer Co.Lab, a cell and gene therapy accelerator co-located with the Bayer Research and Innovation Center (BRIC) in Kendall Square. Portal is also affiliated with the Roche Accelerator.

门户网站是拜耳公司实验室的成员，该实验室是一家细胞和基因治疗加速器，与拜耳研究与创新中心（BRIC）位于肯德尔广场。门户网站还隶属于罗氏加速器。

About Portal Biotechnologies:

关于Portal Biotechnologies：

Portal is a cell engineering platform company focused on enabling next generation cell engineering and cell analytics across research and clinical applications. The company is implementing a simplified approach to intracellular delivery, focused on accelerating advances enabled by the new generation of RNA, gene editing, and molecular design technologies.

Portal Biotechnologies是一家细胞工程平台公司，专注于跨研究和临床应用实现下一代细胞工程和细胞分析。该公司正在实施一种简化的细胞内递送方法，专注于加速新一代RNA，基因编辑和分子设计技术所带来的进步。

Portal’s initial product suite is based on a proprietary mechanical delivery system capable of delivering many different types of cargo to a broad range of cell types. The technology's ability to be used stand-alone or as an integrated component of third-party systems provides a significant opportunity to broadly impact the fields of biological research and cellular therapeutics.

门户网站的初始产品套件基于专有的机械输送系统，能够将多种不同类型的货物输送到各种细胞类型。该技术能够独立使用或作为第三方系统的集成组件使用，为广泛影响生物学研究和细胞治疗领域提供了重要机会。

For more information, please visit https://portal.bio/..

有关更多信息，请访问https://portal.bio/..

About Pear VC:

关于Pear VC：

​​​​Pear VC is a pre-seed and seed stage VC firm that partners with entrepreneurs from their earliest days to build category defining companies. We've invested in top-tier companies including DoorDash, Gusto, Branch, Guardant Health, Aurora Solar, Vanta, Affinity, and so many more. We're company builders, having founded 10+ companies ourselves: we help companies find product-market fit, recruit their first hires, and overcome other critical business challenges.

​​​​Pear VC是一家种子期和种子期风险投资公司，从创业初期就与创业者合作，建立类别定义公司。我们投资了顶级公司，包括DoorDash、Gusto、Branch、Guardant Health、Aurora Solar、Vanta、Affinity等等。我们是公司的建设者，我们自己已经建立了10多家公司：我们帮助公司找到适合市场的产品，招募第一批员工，并克服其他关键的业务挑战。